<DOC>
	<DOC>NCT00631579</DOC>
	<brief_summary>The primary objectives of the study are to evaluate the safety and the efficacy in patients with malignant lymphoma or acute leukemia who are repeatedly administered for SR29142 5 days in two dosage groups. Secondary objectives are to determine the pharmacokinetic (PK) parameters of SR29142 , to assess anti-SR29142 antibody production in patients with malignant lymphoma and acute leukemia, and to estimate the optimal dosage of SR29142 for Japanese patients from the results of efficacy and safety evaluations.</brief_summary>
	<brief_title>Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Patient suffering from: acute leukemia with white blood cell (WBC) count≥ 20,000/mm3 without regard to uric acid level ; or lymphoma,Stage ≥ III without regard to uric acid level; or lymphomas, Stage II with bulky disease; or lymphoma or leukemia, without regard to classification or morphology, with uric acid level ≥ 8.0 mg/dL, and lactate dehydrogenase (LDH) level ≥ twice the upper limit of normal (ULN).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>